Welcome to our dedicated page for WW International news (Ticker: WW), a resource for investors and traders seeking the latest updates and insights on WW International stock.
WW International, Inc. operates the Weight Watchers weight-management platform through digital, workshop and clinical subscription offerings. Company news commonly covers subscriber trends, subscription revenue, adjusted operating measures and the balance between its Behavioral business and its Clinical business.
Recurring updates also include expansion of the Med+ clinical offering, access to FDA-approved GLP-1 treatment options through affiliated medical groups, debt-reduction actions involving its term loan, and governance changes such as board appointments, committee assignments and interim executive-leadership structure.
Weight Watchers (Nasdaq: WW) appointed Heather Thiltgen to its Board of Directors, effective April 20, 2026. Ms. Thiltgen is president of Presbyterian Health Plan and previously led WellSense Health Plan. The Board expanded to six independent members; she joins the Compensation and Benefits Committee and is expected to stand for election at the 2026 annual meeting.
Her expertise includes expanding access to GLP-1 therapies, navigating payor-provider regulation, rebuilding membership bases, and scaling telehealth and pharmaceutical solutions.
WW (NASDAQ: WW) will offer Eli Lilly’s newly FDA-approved oral GLP-1 Foundayo (orforglipron) through its Med+ program beginning April 9, 2026. Med+ members gain access to once-daily, oral treatment with board-certified clinician care, insurance support, and the Weight Watchers GLP-1 Success behavioral program.
Self-pay pricing for Foundayo starts at $149 per month for the lowest dose, with price varying by dose. Weight Watchers reports members who engaged the GLP-1 Success Program for 12 months lost 29.1% more body weight on average than non-engaged members.
WW (Nasdaq: WW) announced updates to its Board committee composition after appointing Lisa Gavales and Sue Gove as independent directors on April 9, 2026. Committee chairs and members were named for Audit, Compensation and Benefits, Nominating and Corporate Governance, and Strategy and Finance.
The Board confirmed the Office of the CEO will remain led by the existing Transition Committee—CFO Felicia DellaFortuna and COO Jon Volkmann—with counsel from the new directors, and decided not to appoint an interim CEO while a permanent CEO search continues with an executive search firm.
Weight Watchers (Nasdaq: WW) appointed Lisa Gavales and Sue Gove as independent directors, effective April 7, 2026. Following the appointments the Board totals six directors, all independent. Both bring consumer, digital and senior leadership experience to support the company’s strategic transformation and member-acquisition efforts.
Ms. Gavales adds e-commerce and brand-engagement expertise; Ms. Gove contributes CEO/COO/CFO experience and public-board experience. Both will serve until the 2026 annual meeting and are expected to stand for election.
Weight Watchers (Nasdaq: WW) announced a leadership transition effective April 3, 2026, after Tara Comonte’s departure on March 31, 2026. The Board formed a Transition Committee and established an Office of the CEO led by CFO Felicia DellaFortuna and COO Jon Volkmann while conducting a CEO search.
The company appointed Debra Cotter as chief legal officer and secretary effective April 10, 2026, and noted director resignations. Weight Watchers reaffirmed its Q1 2026 subscriber estimates and full‑year 2026 financial guidance.
Weight Watchers (NASDAQ: WW) expanded collaboration with Novo Nordisk to offer Med+ members subscription pricing for Wegovy, promising the lowest available self-pay prices and up to $1,200 annual savings.
Eligible members can pre-pay for 3, 6, or 12 months, with discounts on pens and pills and access to Wegovy across multiple doses.
Weight Watchers (Nasdaq: WW) reported fourth-quarter and full-year 2025 results on March 16, 2026. Q4 total revenue was $163 million, Q4 net loss was $6 million (3.6% margin) and Q4 Adjusted EBITDA was $18 million (11.1% margin). End of period subscribers totaled 2.8 million, including 130,000 clinical subscribers, up 42% year-over-year.
The company exceeded its 2025 revenue and Adjusted EBITDA guidance and provided Q1 2026 subscriber estimates and full-year 2026 guidance: revenue of $620–$635 million and Adjusted EBITDA of $105–$115 million.
Weight Watchers (NASDAQ: WW) released a GLP-1 Results Report showing Med+ members who used the GLP-1 Success Program lost substantially more weight than those on medication alone. Key metrics: 7.4 lb average first-month loss, 21% average weight loss at 12 months, and 20.5% at 24 months. The report also cites improved clinical measures and higher member-reported quality-of-life gains.
The analysis highlights up to 61.3% more weight loss in month one for engaged members and over 30% greater 12-month loss versus select competitors.
WW (NASDAQ: WW) will release fourth-quarter and full-year 2025 results for the period ended December 31, 2025, before market open on Monday, March 16, 2026.
The company will host a conference call at 8:30 a.m. ET that same day and will provide a live webcast and a replay on corporate.ww.com available for at least 90 days.
Weight Watchers (NASDAQ: WW) announced a strategic partnership with PVOLVE on February 10, 2026 to add clinically validated strength, mobility, and stability workouts into Weight Watchers programs. The collaboration integrates PVOLVE classes into Core, Core+, Med+, GLP-1 Success and Menopause tracks, offers a 1,700+ on-demand library at reduced rates, and a curated starter kit. Company data cites Med+ members engaged with the program lost 61.3% more weight at one month and 29.1% more at 12 months versus medication alone; a 12-week PVOLVE program showed 19% improved lower-body strength.